[Skip to the page](#main)

[Boston / Peptide care primer](/)

[Start here](/primer/)

[My notes](/primer-questions/#notebook)

Explore 

Understand the words 

- [Start with the basics](/primer/)

- [Approved medicine](/medicine-primer/)

- [Pharmacy-made medicine](/compounding-primer/)

- [Research labels](/research-primer/)

Find and check care 

- [Care in Boston](/boston-primer/)

- [Online care](/telehealth-primer/)

- [The care visit](/visit-primer/)

- [Check a licence](/licence-primer/)

Compare and prepare 

- [The full cost](/cost-primer/)

- [Insurance terms](/insurance-primer/)

- [Questions to keep](/primer-questions/)

- [Before an injection](/safety-primer/)

- [Check an offer](/careful-with/)

- [Further reading](/source-primer/)

[Open my notebook](/primer-questions/#notebook)

[Start](/)

Research labels 

Research labels 

# Does a research label mean it is medicine? 

A laboratory label does not prove a product can be offered as treatment. Ask what permits the exact product to be given to a patient. 

Term in plain words 

## Research use only 

“Research use only” labels a substance for research, such as laboratory work, rather than treatment. The wording does not give permission to inject it into a person. 

## Check these points 

- **Treat the label as a question to resolve**
  Federal drug review is handled by the FDA, short for Food and Drug Administration. 

  As of September 26, 2026, FDA warning letters say research labels do not excuse marketing unapproved products for human treatment. 

  A warning letter states the agency’s allegations. It is not a court judgment.

- **Check the exact substance**
  FDA records checked September 26, 2026 show no US approved product for BPC-157 or ipamorelin. 

  These are ingredient names found in peptide offers. A familiar name is not evidence of approval.

- **Ask about claims of new permission**
  Compounding means a pharmacist or doctor makes or changes a medicine for a patient. A larger business registered with the FDA can also make it. 

  Individuals or groups requested permission from the FDA to use an ingredient in compounding, then withdrew that request. As of September 26, 2026, taking it back does not mean the FDA approved the ingredient or allowed pharmacies to use it. 

  Ask for the dated FDA decision that allows the exact product or ingredient to be used. A headline about a withdrawn request does not answer that question.

## Notes that explain the checks 

### One clear federal answer 

As of September 26, 2026, the FDA says federal law prohibits compounding retatrutide and cagrilintide. 

Those are drug ingredient names. Ask what the service is actually offering if either appears in a treatment plan. 

### Advice is not a rule change 

An FDA advisory panel gives advice; its vote alone cannot change the compounding rules, as of September 26, 2026. 

For an approved medicine, ask for the FDA page confirming approval and the approved label. For a pharmacy-made medicine, ask which current rule allows its ingredient to be used. A draft rule or a list of topics for a meeting does not show that permission. 

[Further reading for this question →](/source-primer/#research)

## Keep this question 

Which official record supports this product being offered as treatment? 

Add to my notes 

Copy it to paper, or save it here and use “My notes” to find it again on this phone or computer. 

[Open my notebook →](/primer-questions/#notebook)

## Keep going with the question that matters next. 

Pick a term, check or practical step. 

[Check an offer](/careful-with/)

[Pharmacy-made medicine](/compounding-primer/)

Boston / Peptide care primer 

[Start with the basics](/primer/)

[Further reading](/source-primer/)

[My notes](/primer-questions/#notebook)

[Text version](/research-primer/index.md)

This is Boston peptide care put into plain words: a guide for asking better questions, never a clinic or a seller.